Kalaris Therapeutics, Inc. (KLRS)
9.13
-1.29
(-12.38%)
USD |
NASDAQ |
Dec 19, 16:00
9.41
+0.28
(+3.07%)
After-Hours: 06:46
Kalaris Therapeutics Total Assets (Quarterly): 81.18M for Sept. 30, 2025
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| CEL-SCI Corp. | 20.34M |
| AIM ImmunoTech, Inc. | 5.494M |
| IGC Pharma, Inc. | 9.743M |
| NovaBay Pharmaceuticals, Inc. | 3.487M |
| Protalix Biotherapeutics, Inc. | 82.26M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 39.31M |
| Shareholders Equity (Quarterly) | 41.86M |
| Debt to Equity Ratio | 0.0369 |
| Current Ratio | 12.89 |
| Net Debt Paydown Yield | 1.38% |